Familial Hypercholesterolemia
High genetically predicted LDL level tied to lower type 2 diabetes risk, elevated CAD risk
High genetically predicted LDL was inversely associated with risk for incident diabetes, whereas the opposite trend was observed for CAD risk, researchers reported.
Lack of Lp(a) screening a ‘missed opportunity’; promising therapies on the horizon
Improved screening for elevated lipoprotein(a) levels among all adults may improve CVD risk assessment and outcomes, especially with multiple Lp(a)-lowering therapies currently in the research pipeline, a speaker reported.
Obicetrapib tied to sizable LDL lowering on top of other therapies in high-risk patients
CHICAGO — In patients with heterozygous familial hypercholesterolemia with high LDL despite being on optimal medical therapy, obicetrapib greatly lowered LDL levels compared with placebo, according to the results of the BROOKLYN trial.
Managing high cholesterol during pregnancy ‘challenging,’ medications lack safety data
Most lipid-lowering medications lack safety data for pregnant and lactating women, complicating management of hyperlipidemia and hypertriglyceridemia, but data suggest statins can be used for those at high risk for cardiovascular events.
2018 ACC/AHA Multi-Society Cholesterol Guideline Overview
NLA document issued to optimize screening, management of lipids in reproductive-age women
The National Lipid Association has issued a clinical consensus statement on the management of dyslipidemia in women of reproductive potential, with a focus on considerations for pharmacologic options, a speaker reported.
Ace the Case #3: A 54-Year-Old South Asian Male with a History of Cardiac Percutaneous Intervention
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Ace the Case #2 - A 62-Year-Old Woman with Diabetes with an LDL-C of 53 mg/dL
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Ace the Case #1 – A 34-Year-Old Woman with Severe Heterozygous Familial Hypercholesterolemia (HeFH)
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Ballantyne: Prevention of heart disease crucial, core of NLA’s mission
Prevention of heart disease will do more good in the long run than procedures to treat advanced heart disease, the incoming president of National Lipid Association said at the NLA’s Scientific Sessions.